Trial Profile

Efficacy, tolerability and pharmacokinetics of GS 9451 in patients with genotype 1a or 1b hepatitis C

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedroprevir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

28 Sep 2012 Primary endpoint 'Viral-load' has been met.
03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
31 Oct 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com